ARMH1: A New Marker for Poor Outcomes in Pediatric AML
Author Information
Author(s): Bakhtiari Mojtaba, Jordan Sean C., Mumme Hope L., Sharma Richa, Shanmugam Mala, Bhasin Swati S., Bhasin Manoj
Primary Institution: Aflac Cancer and Blood Disorders Center, Children Healthcare of Atlanta, Atlanta, GA, United States
Hypothesis
Is ARMH1 a significant biomarker associated with poor outcomes in pediatric acute myeloid leukemia (pAML)?
Conclusion
ARMH1 is associated with poor outcomes in pediatric AML and may serve as a potential target for therapy.
Supporting Evidence
- ARMH1 expression is significantly elevated in blast cells of patients who relapsed or have a high-risk cytogenetic profile.
- Knockdown of ARMH1 led to a significant reduction in cell proliferation and migration.
- ARMH1 is correlated with a six-gene leukemia stem cell score associated with poor outcomes.
- Pharmacological inhibition of CPT1A resulted in ARMH1 downregulation.
Takeaway
ARMH1 is a gene that can help doctors understand how serious a child's leukemia is and how to treat it better.
Methodology
The study analyzed bone marrow samples from 21 pediatric AML patients using single-cell RNA sequencing and functional assays to evaluate the impact of ARMH1 on cell proliferation and migration.
Limitations
The study lacks animal models to complement in vitro findings and has limited understanding of ARMH1's effects on immune cells.
Participant Demographics
Pediatric patients with acute myeloid leukemia.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website